Full Press Release Details
Immuron CEO, Steven Lydeamore
Emerging Growth Conference
Melbourne, Australia, April 30, 2026:
Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at
the Emerging Growth Conference on Thursday 7th May 2026 (10:15am - 10:45am U.S. Eastern Time).
Please submit your questions in advance
to Questions@EmergingGrowth.com or ask your questions during the event.
Please register here to ensure you are
able to attend the conference and receive any updates that are released.
This release has been authorised by the directors of Immuron
Chief Executive Officer
Immuron Limited (ASX: IMC, NASDAQ:
IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies
for the treatment of infectious diseases.
Travelan is an orally administered
passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea, a digestive tract disorder
that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan is a highly purified tabletized preparation
of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization
and the pathology associated with travelers' diarrhea. In Australia, Travelan is a listed medicine on the Australian Register
for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers' Diarrhea, reduce the risk of minor gastro-intestinal
disorders and is antimicrobial. In Canada, Travelan is a licensed natural health product (NPN 80046016) and is indicated to reduce
the risk of Travelers' Diarrhea. In the U.S., Travelan is sold as a dietary supplement for digestive tract protection.
Travelers' diarrhea (TD)
TD is generally defined as the passage of
3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps, fever, blood/mucus in
the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any resource-limited destinations (Leung
et al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations in lower- and middle-income
regions (Steffen, 2017). Deployed US military personnel, essentially representing a long-term traveller population, are particularly
affected given their population dynamics and the context in which they seek care and treatment (Connor et al., 2012). Diarrhea is the
leading infectious disease threat to the overall health and preparedness of deployed US armed forces, with diarrheagenic E. coli, Campylobacter
spp., and Shigella spp. among the most commonly reported etiologies (Riddle et al., 2006).
Immuron Platform Technology
Immuron's proprietary technology
is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing
highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment
of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses
this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying
nature of Immuron's platform technology enables the development of medicines across a large range of infectious diseases. The platform
can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.
IMM-124E (Travelan )
IMM-124E was developed using Immuron's platform
technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised during pregnancy with a vaccine containing
the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in the vaccine to produce high levels of antibodies
against selected surface antigens from the most common strains of ETEC. (Otto et al., 2011)
The resultant hyperimmune colostrum IMM-124E from
ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for ETEC antigens LPS, CFA-I and Flagellin (Sears
The antibodies produced in IMM-124E
have been found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated cattle) against a wide range
of LPS antigens including both the variable O-polysaccharide region and the preserved oligosaccharide core R' region of LPS
from the 13 serotypes used in the ETEC vaccine.
IMM-124E is manufactured into a tablet
form referred to as Travelan .
Immuron is developing IMM-529 as an adjunctive therapy
in combination with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection (CDI).
IMM-529 antibodies targeting Clostridioides difficile (C. diff) may help to clear CDI infection and promote a quicker re-establishment
of normal gut flora, providing an attractive oral preventative for recurrent CDI.
Immuron is collaborating with Dr. Dena Lyras and her team
at Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised to generate
hyperimmune bovine colostrum (HBC) that contains antibodies targeting three essential C. diff virulence components. IMM-529 targets Toxin
B (TcB), the spores and the surface layer proteins of the vegetative cells.
This unique 3-target approach has yielded promising results
in pre-clinical infection and relapse models, including (1) Prevention of primary disease (80% P =0.0052); (2) Protection of disease recurrence
(67%, P <0.01) and (3) Treatment of primary disease (78.6%, P<0.0001; TcB HBC). Importantly IMM-529 antibodies cross-react with
whole cell lysates of many different human strains of C. diff including hypervirulent strains.
To our knowledge, IMM-529 is, to date, the only
investigational drug that has shown therapeutic potential in all three phases of the disease (Hutton et al., 2017).
Immuron has an exclusive distribution agreement
with Calmino goup AB for the territories of Australia and New Zealand for ProIBS . ProIBS - to help patients treat IBS symptoms
ProIBS is a certified medical device for the treatment of IBS symptoms such as abdominal pain, bloating and unsettled bowel movements
(diarrhoea and/or constipation). ProIBS contains AVH200 , derived from the plant Aloe barbadensis. Mill. AVH200 has gel
forming components which support the intestinal mucosal barrier. As IBS is known to affect individuals for a long period of time, it
is essential to have a treatment appropriate for long-term use -as ProIBS is. The product is safe, and no interactions with
other medications are known. Science-driven innovative Calmino group AB, the developer of ProIBS , conducted a usability study among
1,003 users. PROIBS was helpful for 94% of them. 91% of the users experienced an improvement in daily life and 98% would recommend
PROIBS to someone else. To learn more please check: www.proibs.eu.
Irritable bowel syndrome (IBS) is a common condition where
you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress levels
or mood. IBS affects around 3 out of every 10 people.
Females are more likely than males to be affected.
Some key symptoms of IBS include: abdominal pain or discomfort; stomach bloating and wind; chronic diarrhoea or constipation, or alternating
between the two.(healthdirect.gov.au) According to available data, the IBS treatment market in Australia is estimated to be a part of
the broader "Digestives & Intestinal Remedies" market, generating a revenue of around AU$221.14 million in 2025, with a
projected annual growth rate of 3.28%.(Statista)
Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea
during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012.
Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine
antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative. Sci Rep 7, 3665 (2017).
Leung AK, Robson WL, Davies HD. Travelers' diarrhea.
Adv Ther. Jul-Aug; 23(4): 519-27; 2006
Otto W, Najnigier B, Stelmasiak T
and Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused
by enterotoxigenic Escherichia coli in volunteers Scandinavian Journal of Gastroenterology 46: 862- 868; 2011.
Riddle MS, Sanders JW, Putnam SD,
and Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers' (US military and similar populations): A
systematic review. American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.
Sears KT, Tennant SM, Reymann MK,
Simon R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic
Escherichia coli Hyperimmune Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017.